Yng Nghymru, arfarnwyd Kalydeco gan Grŵp Strategaeth Feddyginiaethau Cymru Gyfan (AWMSG) ar 8 Mai 2013. Roedd hyn yn cwblhau proses a ddechreuwyd adeg y cysylltiad cyntaf â Vertex, gweithgynhyrchydd Kalydeco, ym mis Gorffennaf 2011 pan ofynnwyd iddynt gymryd rhan ym mhroses arfarnu AWMSG. Ar ôl arfarnu Kalydeco ar 8 Mai, ac mewn cyfarfod cyhoeddus, cyhoeddodd AWMSG mai’r cyngor oedd na ddylwn argymell defnyddio Kalydeco yn GIG Cymru. Er y bydd oddeutu 10 diwrnod arall fel arfer nes i mi gael cyngor ysgrifenedig gan AWMSG, gan fod rhaid caniatáu amser ar gyfer cyflwyno apeliadau, rwyf wedi penderfynu cyhoeddi’r datganiad hwn er mwyn egluro’r ffordd ymlaen.
In Wales, Kalydeco was appraised by the All Wales Medicines Strategy Group (AWMSG) on 8 May 2013, concluding a process which commenced when they first made contact with Vertex, the manufacturer of Kalydeco, in July 2011 and requested their engagement in the AWMSG appraisal process.  Following the appraisal of Kalydeco on  8 May, and at a meeting  held in public, AWMSG announced their advice to me  was  to not recommend Kalydeco for use in NHS Wales. Although it will normally be  a further 10 days or so before I receive the written advice from AWMSG, as they must now allow time for appeals to be lodged, I have decided to issue this statement to clarify the way forward.